Market Place
Sourcing Support
CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
28 Nov 2022 //
FINANCEYAHOO
Final data from the AGENT study confirms topline results
25 Nov 2022 //
PRNEWSWIRE
Isofol Medical AB (publ) publishes interim report, January-September 2022
11 Nov 2022 //
PRNEWSWIRE
Isofol appoints nomination committee ahead of the Annual General Meeting 2023
03 Nov 2022 //
PRNEWSWIRE
Isofol reports data from the AGENT study
07 Sep 2022 //
PRNEWSWIRE
Isofol provides update on the AGENT study
31 Aug 2022 //
CISION
Isofol Medical AB (publ) publishes interim report, January-June 2022
23 Aug 2022 //
PRNEWSWIRE
Invitation to presentation of Isofol´s report for the second quarter of 2022
15 Aug 2022 //
PRNEWSWIRE
Invitation to presentation of Isofol`s report for the first quarter of 2022
03 May 2022 //
PRNEWSWIRE
Isofol initiates data assessment in Phase III colorectal cancer drug trial
26 Apr 2022 //
CLINICALTRIALSARENA
Isofol announces start of study data analysis of phase III AGENT study
22 Apr 2022 //
PRNEWSWIRE
Isofol Medical AB (publ) will not reach 300 PFS events
03 Dec 2021 //
BIOSPACE
Arfolitixorin Lands FDA Fast Track Designation for Advanced CRC
26 Nov 2021 //
TARGETEDONC
Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin
23 Nov 2021 //
PRNEWSWIRE
Isofol publishes prospectus in connection with the fully guaranteed rights
25 May 2021 //
PRNEWSWIRE
Isofol`s Board of Directors resolves on a fully guaranteed rights issue
18 May 2021 //
PRNEWSWIRE
Isofol`s Board of Directors resolves on a fully guaranteed rights issue
18 May 2021 //
PRNEWSWIRE
Isofol receives notice that Clinical Use Patent in Europe for Drug arfolitixorin
22 Mar 2021 //
PRNEWSWIRE
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT
19 Mar 2021 //
PRNEWSWIRE
Isofol to present gene expression results from completed Phase I/IIa ISO-CC-005
15 Jan 2021 //
PRNEWSWIRE
Isofol reaches 440 patients in global Phase III AGENT study
09 Dec 2020 //
PRNEWSWIRE
Isofol reaches 440 patients in global Phase III AGENT study
08 Dec 2020 //
PRNEWSWIRE
Isofol announces licensing agreement for Paladin Labs to arfolitixorin
02 Nov 2020 //
BIOSPACE
Invitation to a conference call & webcast Isofol license agreement Paladin Labs
02 Nov 2020 //
PRNEWSWIRE
Strengthened patent protection for arfolitixorin in Japan
31 Aug 2020 //
PRNEWSWIRE
ISOFOL ENTERS LICENSING AGREEMENT WITH SOLASIA COMMERCIALIZE ARFOLITIXORIN
17 Aug 2020 //
ISOFOLMEDICAL
Isofol enters licensing agreement with Solasia to develop arfolitixorin in Japan
12 Aug 2020 //
PRNEWSWIRE
Isofol`s Rights Issue Oversubscribed
02 Jun 2020 //
PRNEWSWIRE
Isofol Publishes Prospectus in Connection With the Fully Guaranteed
14 May 2020 //
PRNEWSWIRE
Isofol`s Board of Directors Resolve on a Fully Guaranteed Rights SEK 150 M
07 May 2020 //
PRNEWSWIRE
Isofol`s Drug Candidate Arfolitixorin Receives Add Clinical Patent Approval
04 May 2020 //
PRNEWSWIRE
The First Patient Included in Japan in Isofol`s Phase 3 AGENT Study
18 Feb 2020 //
PR NEWSWIRE
The First Patient Included in Australia in Isofol`s Phase 3 AGENT Study
24 Jan 2020 //
PRNEWSWIRE
Patent Approved in Japan for Isofol`s Drug Candidate Arfolitixorin
20 Dec 2019 //
PR NEWSWIRE
